BioVie Inc. – Special Call

Craig Brelsford

Hello. This is Craig Brelsford with RedChip Companies. Thank you for joining today’s event with BioVie, which trades on the NASDAQ under the ticker BIVI. With us today, we have Cuong Do, President and CEO of BioVie. We will begin with a brief presentation in a moment and then we will answer your questions. Submit your question at any time by using the Q&A tool at the bottom of the Zoom window.

Before we begin, please allow me to read the safe harbor statement. This call may contain forward-looking statements within the meaning of the Private Securities Ligation Reform Act of 1995. All statements pertaining to future financial and/or operating results, along with other statements about the future expectations, beliefs, goals, plans or prospects expressed by management constitute forward-looking statements. Any statements that are not historical facts should also be considered forward-looking statements. Of course, forward-looking statements involve risks and uncertainties.

I now turn this webinar over to Cuong. Go ahead.

Cuong Viet Do
President, CEO & Director

Good afternoon, Craig. Thank you for joining. Good afternoon, everyone. Thank you for joining our update today. I’m very excited to share with you this afternoon some exciting progress at the company, right?

As you know, we have several clinical trials underway right now, which makes it — I believe we have one of the most exciting biotech companies around with an exciting portfolio. You may know that we have a Parkinson’s clinical trial that is underway. It is a Phase II trial, and now we can pick up — enrollment has picked up relatively quickly within the last few weeks, and we can now project to be fully enrolled by the end of 2025. As a result